| 1 |
30663560 | Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. | 2020 |
1 |
| 2 |
30554037 | Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells. | 2019 Feb |
1 |
| 3 |
27030119 | [Incretin therapies and multifactorial clinical approach to cardiometabolic patients]. | 2016 Mar |
1 |
| 4 |
26788106 | Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors. | 2015 |
2 |
| 5 |
22382611 | Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide. | 2012 Mar |
2 |
| 6 |
21871831 | Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. | 2011 Dec |
2 |
| 7 |
20380648 | Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. | 2010 Apr |
1 |
| 8 |
19182763 | Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. | 2009 Jan |
1 |
| 9 |
19952298 | Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. | 2009 Dec |
1 |
| 10 |
18020966 | The entero-insular axis: implications for human metabolism. | 2008 |
1 |
| 11 |
18201204 | Effects of exendin-4 on islets from type 2 diabetes patients. | 2008 Jun |
1 |
| 12 |
18402245 | Glucagon-like peptide 1 based therapy for type 2 diabetes. | 2008 Feb |
1 |
| 13 |
18630617 | [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus]. | 2008 Apr |
1 |
| 14 |
27056542 | Incretin-based Therapies for Type 2 Diabetes. | 2008 |
1 |
| 15 |
17263764 | Incretins and other peptides in the treatment of diabetes. | 2007 Mar |
2 |